The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its future within the broader sector now presents questions about potential gains. Alternative versions are diminishing patent protection , causing concerns that investing in companies heavily reliant to Viagra's former position could be a problem